Clinical Trial

Effects of Quercetin on Cardiometabolic Outcomes

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated February 27, 2026 (before its estimated August 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
Cardiovascular disease, type 2 diabetes mellitus and associated diseases combined are the leading health burden and cause of mortality worldwide; therefore, the necessity for an intervention is paramount. Dietary interventions to improve cardiometabolic health are highly sought after as they possess less risk than pharmacological drugs. It has been postulated that Quercetin may be beneficial in improving cardiometabolic outcomes. However, to date, no research has explored this using a placebo randomized intervention.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-01-19; most recent amendment 2026-02-25.
Status change: Not Yet Recruiting → Recruiting 2024-07-02
Trial Details
NCT Number NCT06230861
Lead Sponsor University of Central Lancashire
Collaborators: DoNotAge.org
Conditions Cardiometabolic Syndrome
Enrollment 40 participants
Start Date 2024-03-01
Primary Completion 2026-08-01 (estimated)
Study Completion 2026-12-01 (estimated)
Updated on ClinicalTrials.gov 2026-02-27